Literature DB >> 3319348

Clinical pharmacokinetic significance of the renal tubular secretion of digoxin.

G Koren1.   

Abstract

Tubular secretion appears to be a major route of the renal elimination of digoxin. Secretion of the drug by the tubules is modulated by renal blood flow, by a number of commonly coadministered drugs (e.g. quinidine, spironolactone, verapamil, amiodarone), and by age. The maximal transport capacity does not appear to be achieved with clinically relevant concentrations. The tubular transport of digoxin does not appear to be associated with the anionic or cationic transport systems, nor the Na+/K+-ATPase receptor. Further studies are needed to elucidate the exact mechanisms involved in the transtubular movement of the glycoside.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319348     DOI: 10.2165/00003088-198713050-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  48 in total

1.  Digoxin interactions. The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides.

Authors:  K E Pedersen
Journal:  Acta Med Scand Suppl       Date:  1985

2.  Renal tubular secretion of digoxin.

Authors:  E Steiness
Journal:  Circulation       Date:  1974-07       Impact factor: 29.690

3.  William Withering: An account of the foxglove and some of its medical uses 1785-1985.

Authors:  C Fisch
Journal:  J Am Coll Cardiol       Date:  1985-05       Impact factor: 24.094

4.  In vivo determination of cellular uptake in the kidney.

Authors:  M Silverman; C Trainor
Journal:  Fed Proc       Date:  1982-12

5.  Renal handling and effects of [3H]digoxin and interactions with quinidine in the avian kidney.

Authors:  A Milton; B Odlind; L Dencker
Journal:  Acta Physiol Scand       Date:  1986-05

6.  Amiloride-induced changes in digoxin dynamics and kinetics: abolition of digoxin-induced inotropism with amiloride.

Authors:  S Waldorff; P B Hansen; H Kjaergård; J Buch; H Egeblad; E Steiness
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Effect of spironolactone on the renal clearance of digoxin in dogs.

Authors:  M S O'Brien; L F Salamone; T P Gibson
Journal:  J Pharmacol Exp Ther       Date:  1985-07       Impact factor: 4.030

8.  Interaction between quinidine and digoxin.

Authors:  E B Leahey; J A Reiffel; R E Drusin; R H Heissenbuttel; W P Lovejoy; J T Bigger
Journal:  JAMA       Date:  1978-08-11       Impact factor: 56.272

9.  Effect of nifedipine on serum digoxin concentration and renal digoxin clearance.

Authors:  J B Schwartz; P J Migliore
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

10.  Postmortem digoxin tissue concentration and organ content in infancy and childhood.

Authors:  A R Hastreiter; R L van der Horst
Journal:  Am J Cardiol       Date:  1983-08       Impact factor: 2.778

View more
  12 in total

1.  MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.

Authors:  T Sakaeda; T Nakamura; M Horinouchi; M Kakumoto; N Ohmoto; T Sakai; Y Morita; T Tamura; N Aoyama; M Hirai; M Kasuga; K Okumura
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.200

2.  Interaction between digoxin and indomethacin or ibuprofen.

Authors:  H S Jørgensen; H R Christensen; J P Kampmann
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 3.  The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Authors:  Pietro Fagiolino; Rosa Eiraldi; Marta Vázquez
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

5.  Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxin.

Authors:  J H Soul-Lawton; B C Weatherley; J Posner; G Layton; R W Peck
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 6.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

7.  The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects.

Authors:  C Weber; L Banken; H Birnboeck; S Nave; R Schulz
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

Review 8.  Pharmacokinetic drug interactions with rifampicin.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

9.  A clinical assessment of the potential for pharmacological interaction between nimesulide and digoxin in patients with heart failure.

Authors:  E Baggio; F Maraffi; C Montalto; M L Nava; L Torti; I Casciarri
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 10.  Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors.

Authors:  C Steinberg; D A Notterman
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.